Top 4 Health Care Stocks That May Crash This Quarter
Portfolio Pulse from Avi Kapoor
Four health care stocks, PepGen Inc. (PEPG), CalciMedica, Inc. (CALC), Oramed Pharmaceuticals Inc. (ORMP), and FibroGen, Inc. (FGEN), are considered overbought as of Feb. 2, 2024, based on their RSI values. Recent developments and price actions for each company are highlighted, with PEPG and FGEN showing significant gains, while CALC and ORMP experienced declines.
February 02, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
FibroGen's stock soared 104% after announcing a trial completion, with an RSI of 86.52. Despite being overbought, the momentum could attract more interest.
The dramatic stock increase and high RSI reflect strong recent performance, but being overbought raises the risk of a short-term correction.
CONFIDENCE 75
IMPORTANCE 85
RELEVANCE 90
NEUTRAL IMPACT
PepGen Inc. recently dosed the first patient in a Phase 2 trial, leading to a 79% stock increase over five days. With an RSI of 84.56, it's considered overbought.
The significant stock price increase and high RSI indicate strong recent performance but also suggest potential for a short-term pullback due to being overbought.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
CalciMedica announced a $55 million private placement, boosting its stock by 55% over the past month. However, a recent 16.7% drop and an RSI of 70.24 suggest volatility.
The recent private placement and stock gain are positive, but the sharp drop and high RSI suggest the stock may face short-term downward pressure.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 85
NEGATIVE IMPACT
Oramed entered a joint venture, leading to a 24% stock increase over five days. However, a 5.5% recent drop and an RSI of 70.03 indicate potential instability.
The joint venture and stock increase are positive, but the recent drop and borderline overbought status may lead to short-term challenges.
CONFIDENCE 65
IMPORTANCE 70
RELEVANCE 80